logo

For the Inventor, By the Inventor

Louisville, KY, United States of America

Kyung Aih Kang

This inventor holds 7 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignee: University Of Louisville Research Foundation, Inc.. Active years: 2011-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kyung Aih Kang. Retrieved from https://idiyas.com/inventor/kyung-aih-kang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 42.9

 

Average Co-Inventor Count = 1.7

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:

goldMedal7 out of 398 
 
University Of Louisville Research Foundation, Inc.
 patents

Years Active: 2011-2022

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents
1. 11344633 - Anti-nucleolin agent-conjugated nanoparticles (2022-05-31),
2. 9452219 - Anti-nucleolin agent-conjugated nanoparticles (2016-09-27),
3. 9140707 - Sensors and methods for detecting diseases caused by a single point mutation (2015-09-22),
4. 8758727 - Site specific fluorescence and contrast marker for same (2014-06-24),
5. 8563328 - Fiber-optic biosensor and biosensing methods (2013-10-22),
6. 7883900 - Enhancement of sensitivity of fluorophore mediated biosensing and bioimaging (2011-02-08),
7. 7871573 - Enhancement of sensitivity of fluorophore mediated biosensing and bioimaging (2011-01-18),

Title: Kyung Aih Kang: Innovator in Nanoparticle Technology

Introduction

Kyung Aih Kang is a notable inventor based in Louisville, KY (US). He has made significant contributions to the field of nanoparticle technology, particularly in the development of compositions for cancer treatment. With a total of 7 patents, his work is recognized for its innovative approach to medical applications.

Latest Patents

One of his latest patents involves anti-nucleolin agent-conjugated nanoparticles. This composition comprises an anti-nucleolin agent that is conjugated to nanoparticles, which are non-magnetic, not iron oxide, and not polyacrylamide. Furthermore, this pharmaceutical composition is designed for treating cancer and includes a composition that combines the anti-nucleolin agent with nanoparticles and a pharmaceutically acceptable carrier.

Career Highlights

Kyung Aih Kang is affiliated with the University of Louisville Research Foundation, Inc. His work has been pivotal in advancing the understanding and application of nanoparticles in medical treatments. His innovative research continues to pave the way for new therapeutic strategies.

Collaborations

Some of his notable coworkers include Paula J Bates and Mohammad Tariq Malik. Their collaborative efforts contribute to the ongoing research and development in the field of nanoparticle technology.

Conclusion

Kyung Aih Kang's contributions to nanoparticle technology and cancer treatment exemplify the impact of innovative research in medicine. His work continues to inspire advancements in therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…